Julie Rubinstein net worth and biography

Julie Rubinstein Biography and Net Worth

Julie Rubinstein is the President of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since 2011, she has held a variety of leadership roles and currently oversees Life Sciences Research, Clinical Diagnostics, Drug Discovery, Corporate Marketing and Business Development functions. Ms. Rubinstein was part of the executive team that took the company public in 2019.

Prior to joining Adaptive, Ms. Rubinstein held various worldwide commercial development roles at Pfizer Oncology, primarily focusing on cancer immunotherapy. She also held multiple positions at Johnson & Johnson’s Ethicon Endo-Surgery division, where she helped commercialize a breast cancer diagnostic device in major European markets. She began her career in Morgan Stanley’s Global Health Care Group as a financial analyst. She currently serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York. Ms. Rubinstein holds a dual degree, summa cum laude and Phi Beta Kappa, from the University of Pennsylvania’s Undergraduate Wharton School and Annenberg School of Communications, with a minor in French. She also holds an MBA from Harvard Business School.

What is Julie Rubinstein's net worth?: The estimated net worth of Julie Rubinstein is at least $5.55 million as of April 8th, 2026. Ms. Rubinstein owns 434,188 shares of Adaptive Biotechnologies stock worth more than $5,553,265 as of April 12th. This net worth evaluation does not reflect any other investments that Ms. Rubinstein may own. Learn More about Julie Rubinstein's net worth.
How do I contact Julie Rubinstein?: The corporate mailing address for Ms. Rubinstein and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Julie Rubinstein's contact information.
Has Julie Rubinstein been buying or selling shares of Adaptive Biotechnologies?: In the last ninety days, Julie Rubinstein has sold $992,725.63 in Adaptive Biotechnologies stock. Most recently, Julie Rubinstein sold 30,941 shares of the business's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $14.83, for a transaction totalling $458,855.03. Following the completion of the sale, the chief operating officer now directly owns 434,188 shares of the company's stock, valued at $6,439,008.04. Learn More on Julie Rubinstein's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Susan Bobulsky (Chief Commercial Officer, MRD), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Robert Hershberg (Director), Francis Lo (Insider), Peter Neupert (Director), Jyoti Palaniappan (SVP), Kyle Piskel (CFO), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 56 times. They sold a total of 3,935,632 shares worth more than $60,124,729.80. The most recent insider tranaction occured on April, 8th when CEO Chad M Robins sold 37,263 shares worth more than $566,024.97. Insiders at Adaptive Biotechnologies own 6.4% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 4/8/2026.

Julie Rubinstein Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2026	Sell	30,941	$14.83	$458,855.03	434,188
4/7/2026	Sell	19,060	$13.56	$258,453.60	438,526
4/1/2026	Sell	19,060	$14.45	$275,417.00	451,540
3/23/2026	Sell	19,060	$13.83	$263,599.80	481,906
3/20/2026	Sell	19,060	$13.37	$254,832.20	486,244
3/18/2026	Sell	19,060	$13.18	$251,210.80	490,582
3/16/2026	Sell	19,060	$13.41	$255,594.60	503,596
3/13/2026	Sell	19,060	$12.96	$247,017.60	507,934
3/11/2026	Sell	141,583	$13.29	$1,881,638.07	516,610
3/10/2026	Sell	19,460	$14.68	$285,672.80	643,471
3/9/2026	Sell	30,941	$14.79	$457,617.39	647,809
3/5/2026	Sell	30,941	$16.00	$495,056.00	652,147
3/3/2026	Sell	30,941	$15.67	$484,845.47	583,911
3/5/2025	Sell	59,505	$6.98	$415,344.90	588,249
3/5/2024	Sell	39,070	$3.47	$135,572.90	472,754
3/6/2023	Sell	22,668	$8.57	$194,264.76	336,824
3/7/2022	Sell	4,613	$12.01	$55,402.13
2/26/2021	Sell	15,000	$56.23	$843,450.00	15,000
2/22/2021	Sell	15,000	$59.71	$895,650.00	15,000
2/18/2021	Sell	15,000	$60.92	$913,800.00	15,000
2/16/2021	Sell	15,000	$65.25	$978,750.00	15,000
2/11/2021	Sell	15,000	$63.28	$949,200.00	15,000
2/9/2021	Sell	15,000	$62.41	$936,150.00	15,000
2/4/2021	Sell	15,000	$58.98	$884,700.00	15,000
2/1/2021	Sell	15,000	$55.54	$833,100.00	15,000
1/29/2021	Sell	15,000	$56.28	$844,200.00	15,000
1/27/2021	Sell	15,000	$58.94	$884,100.00	15,000
1/25/2021	Sell	15,000	$66.43	$996,450.00	15,000
1/22/2021	Sell	15,000	$66.84	$1,002,600.00	15,000
1/20/2021	Sell	15,000	$67.59	$1,013,850.00	15,000
1/14/2021	Sell	15,000	$65.62	$984,300.00	15,000
1/12/2021	Sell	15,000	$62.69	$940,350.00	15,000
1/8/2021	Sell	8,814	$60.46	$532,894.44	15,000
1/6/2021	Sell	15,000	$54.89	$823,350.00	15,000
1/4/2021	Sell	15,000	$57.17	$857,550.00	15,000
12/30/2020	Sell	15,000	$59.61	$894,150.00	15,000
12/28/2020	Sell	15,000	$61.58	$923,700.00	15,000
12/24/2020	Sell	15,000	$63.53	$952,950.00	15,000
12/22/2020	Sell	15,000	$63.71	$955,650.00	15,000
10/1/2020	Sell	94,725	$49.00	$4,641,525.00	80,000
9/29/2020	Sell	80,000	$49.00	$3,920,000.00	80,000
7/9/2020	Sell	15,275	$49.00	$748,475.00	15,275
5/11/2020	Sell	80,000	$38.00	$3,040,000.00	80,000
12/30/2019	Sell	55,000	$28.55	$1,570,250.00	35,000
12/27/2019	Sell	80,000	$29.28	$2,342,400.00	35,000

Julie Rubinstein Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $12.79

$12.36

$13.60

50 Day Range

MA: $14.95

$12.41

$18.50

2 Week Range

Now: $12.79

$6.77

$20.76

Volume

3,310,057 shs

Average Volume

2,019,152 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29